Trial Profile
An interventional study to assess patient-reported outcome measures in bradalumab treated patients with moderate to severe plaque psoriasis in Japan
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Brodalumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms ProLOGUE
- Sponsors Kyowa Kirin
- 01 Apr 2023 Results assessing changes in the levels of itching and skin pain after brodalumab treatment in Japanese patients with psoriasis using patient-reported outcomes published in the Journal of Dermatology
- 06 Mar 2023 Status changed from discontinued to completed.
- 06 Mar 2023 Results assessing the effectiveness of brodalumab on self-assessed anxiety and depressive symptoms in Japanese patients with psoriasis published in the Dermatology and Therapy